DOCS Stock Analysis: Doximity | NYSE

Health Information Services | NYSE, USA | Market Cap: 5.948m USD | 12M Return: -38.3% | US26622P1075 | Charts, Fundamentals & Technical Analysis

Medical Network, Clinical Documentation, Telehealth, Scheduling
Total Rating 54
Safety 78
Buy Signal -0.11
Health Care Technology
Sub-Industry Rotation: -24.9
Market Cap: 5.95B
Avg Turnover: 75.2M
Risk 3d forecast
Volatility61.3%
VaR 5th Pctl8.50%
VaR vs Median-10.5%
Reward TTM
Sharpe Ratio-0.51
Rel. Str. IBD79.8
Rel. Str. Peer Group67.9 pctl
Character TTM
Beta1.061
Beta Downside1.332
Hurst Exponent0.499
Choppyness58.0%
Drawdowns 3y
Max DD78.34%
CAGR/Max DD0.08
CAGR/Mean DD0.20
EPS (Earnings per Share) EPS (Earnings per Share) of DOCS over the last years for every Quarter: "2021-09": 0.19, "2021-12": 0.29, "2022-03": 0.21, "2022-06": 0.14, "2022-09": 0.17, "2022-12": 0.22, "2023-03": 0.2, "2023-06": 0.19, "2023-09": 0.22, "2023-12": 0.29, "2024-03": 0.25, "2024-06": 0.28, "2024-09": 0.3, "2024-12": 0.45, "2025-03": 0.32, "2025-06": 0.27, "2025-09": 0.45, "2025-12": 0.46, "2026-03": 0.26, "2026-06": 0.14, "2026-09": 0.19,
EPS CAGR: 13.06%
EPS Trend: 62.3%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of DOCS over the last years for every Quarter: 2021-09: 79.35, 2021-12: 97.876, 2022-03: 93.653, 2022-06: 90.639, 2022-09: 102.185, 2022-12: 115.262, 2023-03: 110.966, 2023-06: 108.469, 2023-09: 113.612, 2023-12: 135.284, 2024-03: 118.057, 2024-06: 126.676, 2024-09: 136.832, 2024-12: 168.603, 2025-03: 138.288, 2025-06: 145.913, 2025-09: 168.525, 2025-12: 185.053, 2026-03: 145.372, 2026-06: 156.618, 2026-09: 174.537,
Rev. CAGR: 15.03%
Rev. Trend: 98.3%
Last SUE: 0.82
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 5.4 years of data, until 10/2026

Jan +1.8% 0
Feb +4.2% 0
Mar -4.9% 14
Apr -5.9% 0
May -7.8% 14
Jun +9.4% 40
Jul +7.1% 22
Aug +25.8% 5
Sep +4.2% 0
Oct -3.4% 5
Nov +13.3% 14
Dec -4.6% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: DOCS Doximity

Doximity, Inc. is a U.S.-based digital platform built for medical professionals, offering a personalized newsfeed that delivers clinical articles, research, peer updates, Op-Med publications, and sponsored content from pharmaceutical manufacturers and health systems. Beyond content, the company provides HIPAA-compliant workflow tools, including the Ask AI assistant, the Scribe clinical documentation tool, telehealth solutions for hospitals, and the AMiION on-call scheduling platform. Its members primarily include physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. Originally founded as 3MD Communications, Inc., the company rebranded to Doximity in June 2010 and is headquartered in San Francisco, California.

The company operates within the Health Care Technology sub-industry (GICS) of the broader Health Care sector, and it has been listed on the NYSE since its IPO in June 2021. Its business model combines a free, membership-driven professional network with monetization through sponsored content from pharmaceutical manufacturers and paid subscriptions for its telehealth and workflow tools sold to hospitals and health systems.

Headlines to Watch Out For
  • Pharma marketing budgets drive subscription revenue growth
  • AI Scribe adoption accelerates workflow tools monetization
  • Physician membership growth reinforces network effect moat
Piotroski VR-10 (Strict) 6.0
Net Income: 139.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.27 > 0.02 and ΔFCF/TA 2.56 > 1.0
NWC/Revenue: 117.4% < 20% (prev 153.2%; Δ -35.77% < -1%)
CFO/TA 0.28 > 3% & CFO 305.7m > Net Income 139.7m
Net Debt (-704.1m) to EBITDA (220.4m): -3.20 < 3
Current Ratio: 6.37 > 1.5 & < 3
Outstanding Shares: last quarter (187.8m) vs 12m ago -6.45% < -2%
Gross Margin: 86.83% > 18% (prev 90.20%; Δ -3.38% > 0.5%)
Asset Turnover: 56.33% > 50% (prev 49.43%; Δ 6.91% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.71 (Total Current Assets 921.5m - Total Current Liabilities 144.6m) / Total Assets 1.09b
B: -0.13 (Retained Earnings -138.7m / Total Assets 1.09b)
C: 0.17 (EBIT TTM 203.6m / Avg Total Assets 1.17b)
D: 5.69 (Book Value of Equity 928.5m / Total Liabilities 163.3m)
Altman-Z'' = 11.39 = AAA
Beneish M -2.69
DSRI: 1.21 (Receivables 166.1m/129.3m, Revenue 661.6m/621.3m)
GMI: 1.04 (GM 90.20% / 86.83%)
AQI: 1.17 (AQ_t 0.13 / AQ_t-1 0.11)
SGI: 1.06 (Revenue 661.6m / 621.3m)
TATA: -0.15 (NI 139.7m - CFO 305.7m) / TA 1.09b)
Beneish M = -2.69 (Cap -4..+1) = A
What is the price of DOCS shares?

As of November 20, 2026, the stock is trading at USD 29.61 with a total of 2,019,865 shares traded. Over the past week, the price has changed by -10.81%, over one month by -5.85%, over three months by +14.99% and over the past year by -38.31%.

Current recommended Stop Loss: 27.90 (which is 5.8% or 1.2 ATR below the current price).

Is DOCS a buy, sell or hold?

Doximity has received a consensus analysts rating of 3.38. Therefore, it is recommended to hold DOCS.

  • StrongBuy: 3
  • Buy: 5
  • Hold: 11
  • Sell: 1
  • StrongSell: 1

What are the forecasts/targets for the DOCS price?
Analysts Target Price 31.5 6.4%
Doximity (DOCS) - Fundamental Data Overview as of 15 November 2026
Market Cap USD = 5.95b (5.95b USD * 1.0 USD.USD)
P/E Trailing = 46.3056
P/E Forward = 24.3902
P/S = 8.9909
P/B = 6.3794
P/EG = 0.5895
Revenue TTM = 661.6m USD
EBIT TTM = 203.6m USD
EBITDA TTM = 220.4m USD
Long Term Debt = 6.95m USD (estimated: total debt 9.15m - short term 2.20m)
Short Term Debt = 2.20m USD (from shortTermDebt, last quarter)
Debt = 9.15m USD (from shortLongTermDebtTotal, last quarter) (leases 9.15m already included)
Net Debt = -704.1m USD (calculated: Debt 9.15m - CCE 713.2m)
Enterprise Value = 5.24b USD (5.95b + Debt 9.15m - CCE 713.2m)
 Interest Coverage Ratio = unknown (Ebit TTM 203.6m / Interest Expense TTM 0.0)
 EV/FCF = 17.54x (Enterprise Value 5.24b / FCF TTM 299.0m)
FCF Yield = 5.70% (FCF TTM 299.0m / Enterprise Value 5.24b)
FCF Margin = 45.20% (FCF TTM 299.0m / Revenue TTM 661.6m)
Net Margin = 21.12% (Net Income TTM 139.7m / Revenue TTM 661.6m)
Gross Margin = 86.83% ((Revenue TTM 661.6m - Cost of Revenue TTM 87.1m) / Revenue TTM)
Gross Margin QoQ = 85.48% (prev 84.87%)
Tobins Q-Ratio = 4.80 (Enterprise Value 5.24b / Total Assets 1.09b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.15m)
Taxrate = 31.38% (63.9m / 203.6m)
NOPAT = 139.7m (EBIT 203.6m * (1 - 31.38%))
Current Ratio = 6.37 (Total Current Assets 921.5m / Total Current Liabilities 144.6m)
Debt / Equity = 0.01 (Debt 9.15m / totalStockholderEquity, last quarter 928.5m)
Debt / EBITDA = -3.20 (Net Debt -704.1m / EBITDA 220.4m)
Debt / FCF = -2.35 (Net Debt -704.1m / FCF TTM 299.0m)
Total Stockholder Equity = 943.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.90% (Net Income 139.7m / Total Assets 1.09b)
RoE = 14.81% (Net Income TTM 139.7m / Total Stockholder Equity 943.7m)
RoCE = 21.42% (EBIT 203.6m / Capital Employed (Equity 943.7m + L.T.Debt 6.95m))
RoIC = 15.25% (NOPAT 139.7m / Invested Capital 916.3m)
WACC = 9.19% (E(5.95b)/V(5.96b) * Re(9.20%) + D(9.15m)/V(5.96b) * Rd(0.0%) * (1-Tc(0.31)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -78.35 | Cagr: -2.59%
[DCF] Terminal Value 71.92% ; FCFF base≈304.3m ; Y1≈294.8m ; Y5≈290.8m
[DCF] Fair Price = 36.85 (EV 3.99b - Net Debt -704.1m = Equity 4.70b / Shares 127.5m; r=9.19% [WACC]; 5y FCF grow -4.19% → 2.50% )
EPS Correlation: 62.31 | EPS CAGR: 13.06% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.33 | Revenue CAGR: 15.03% | SUE: 0.82 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.44 | Chg30d=+6.54% | Revisions=+69% | Analysts=17
EPS current Year (2027-03-31): EPS=1.35 | Chg30d=-0.49% | Revisions=-6% | GrowthEPS=-11.4% | GrowthRev=+5.5%
EPS next Year (2028-03-31): EPS=1.55 | Chg30d=-0.42% | Revisions=+25% | GrowthEPS=+15.1% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +37% (up=19, down=8)